{"title":"The Know-how Post-transplant Skin cancer for Immunotherapy and target therapies.","authors":"Nerina Denaro, Emanuela Passoni, Giulia Murgia, Cinzia Solinas, Gianluca Nazzaro, Angelo Valerio Marzano, Maria Rosaria Campise, Ornella Garrone","doi":"10.1159/000543801","DOIUrl":null,"url":null,"abstract":"<p><p>Kidney transplant recipients are increasing, as is their life expectancy. Due to immunosuppression, skin cancers are the neoplasms more common in this population. Cancer immunotherapy is the choice treatment for squamous cell non-melanoma skin cancer (NMSC) patients who are not candidates for local therapies (radiotherapy and surgery). Basal cell carcinomas, which require systemic therapies, need hedgehog inhibitors (HHi). Special populations such as solid transplant recipients were traditionally excluded from clinical studies. We revised the literature on immunotherapy and hedgehog inhibitors for NMSC in this special population. Immunotherapy might be administered after a multidisciplinary evaluation in selected patients. Previous rejections, high proteinuria, and anti-donor antibody levels might be considered relative contraindications. Hedgehog inhibitors might be prescribed with caution in selected patients, and renal function and further SCC might be evaluated.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-24"},"PeriodicalIF":2.5000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000543801","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Kidney transplant recipients are increasing, as is their life expectancy. Due to immunosuppression, skin cancers are the neoplasms more common in this population. Cancer immunotherapy is the choice treatment for squamous cell non-melanoma skin cancer (NMSC) patients who are not candidates for local therapies (radiotherapy and surgery). Basal cell carcinomas, which require systemic therapies, need hedgehog inhibitors (HHi). Special populations such as solid transplant recipients were traditionally excluded from clinical studies. We revised the literature on immunotherapy and hedgehog inhibitors for NMSC in this special population. Immunotherapy might be administered after a multidisciplinary evaluation in selected patients. Previous rejections, high proteinuria, and anti-donor antibody levels might be considered relative contraindications. Hedgehog inhibitors might be prescribed with caution in selected patients, and renal function and further SCC might be evaluated.
期刊介绍：
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
